Max Healthcare Eyes FY27 Gurgaon Commissioning, FY28 Breakeven

Max Healthcare Institute Limited — Q4 & FY26 Earnings Call (Quarter ended Mar 31, 2026; Call held May 22, 2026)

1. Overall Tone of Management: Optimistic

• Management highlights continued growth (“22nd consecutive quarter of year-on-year growth”) and operating leverage from ramping capacity.
• Confident forward narrative: “continued confidence in the region” (Lucknow) and expectation of “significant operating leverage” as beds ramp.
• While they acknowledge headwinds (oncology drug discontinuation, temporary ALOS/ARPOB impact, project delays historically), they repeatedly frame them as temporary/managed.

2. Key Themes from Management Commentary

• Capacity expansion execution (brownfield + greenfield):
• “phased commissioning of more than 20% additional brownfield capacity” across Mohali, Nanavati (Mumbai), and Max Smart (Delhi); “all the beds will be ready… over the next 2 to 3 months.”
• Expect “another 10% capacity” from the 500-bed greenfield Gurgaon hospital during FY27.
• Detailed commissioning timeline for multiple projects through FY28–FY29.
• Operating leverage / occupancy resilience:
• Despite higher bed capacity, network occupancy stayed >75%, OBDs up 8% YoY.
• Management emphasizes non-linear cost behavior and expects leverage as ramp progresses.
• Oncology mix disruption due to CGHS-linked chemotherapy drug discontinuation:
• Oncology share in inpatient revenues fell to 21% (from 26% in Q4 FY25).
• They explain this as margin- and discount-driven discontinuation and a knock-on effect on OBDs.
• CGHS pricing benefit partially flowing; super-specialty rates pending:
• They quantify net CGHS benefit and indicate remaining portion to flow over coming months.
• Balance sheet / capital discipline:
• Net debt down vs Dec’25; net debt-to-EBITDA “less than 1.”
• Free cash flow generated; capex deployed toward expansion.
• Strategic growth via M&A / geographic expansion:
• Completed acquisition of controlling stake in Kalinga Hospital (Bhubaneswar); “entry into Eastern India.”
• Board approved INR 1,400 crore investment for 700-bed greenfield Lucknow (Shaheed Path).

3. Q&A Analysis

Theme A: Brownfield ramp-up timing & EBITDA contribution

• Core questions
• When will brownfield beds contribute “more meaningfully” to EBITDA?
• Is occupancy/ramp-up “not a problem” as beds open?
• Management response
• Beds are already contributing; EBITDA leverage improves as more beds open because costs aren’t linear.
• Occupancy should remain strong: “we do not open beds if we do not have occupancy.”
• ALOS temporarily higher due to multi-location rollout; impacts ARPOB and EBITDA per bed.
• Notable points
• Clear explanation of why EBITDA impact is phased, not delayed.
• Strong reassurance on occupancy, but admits ALOS/ARPOB pressure is real and temporary.

Theme B: Gurgaon (Sector-56) greenfield commissioning & breakeven

• Core questions
• Confirm commissioning by end of FY27; any further delays?
• Phase-wise operationalization and breakeven timing; expected bed counts in FY28.
• Management response
• Confirmed: “expecting commissioning by the end of the year.”
• For FY28: “breaking even within the year.”
• Phase-wise staffing: start with ~200-odd beds; ramp balance after breakeven.
• Provided analogy to Dwarka ramp (breakeven earlier than guided).
• Strength / evasiveness
• They avoid detailed loss/EBITDA drag quantification (analyst asked for drag; management said it’s “very tough” due to patient/specialty mixing).

Theme C: Oncology drug discontinuation: magnitude, permanence, and reversal

• Core questions
• Why was oncology decline “sharp” vs earlier quantified impact?
• Will oncology share return to prior levels? When?
• Is the impact only on drugs/daycare or also on beds/OBDs?
• Management response
• Discontinuation affects both top line and OBDs: OBDs down 5–6% in oncology.
• Some impact is permanent: “some of this is permanent… we do not expect the share of oncology come back to 25–26%… hover around 21–22%.”
• Replacement protocols: they imply not feasible to run at minus-margin; other specialties compensate.
• Clarified CGHS benefit timing: super-specialty rates partially pending; remaining portion flows over the year.
• Notable
• Strongly framed as structural mix change, not a one-off that will fully reverse.

Theme D: CGHS rate revision: timing and remaining flow-through

• Core questions
• Has CGHS benefit started in Q4?
• How much remains to flow (super-specialty rates)?
• Management response
• “All except the super specialty rates” started; remaining INR 25–30 crore per annum to phase out.
• Later clarified: out of INR 140 crore net benefit, INR 30–40 crore yet to flow; “about INR 100–110 crore has already flown.”
• Evasiveness
• No precise quarter-by-quarter schedule; uses qualitative “next few months / during the year.”

Theme E: Doctor cost inflation & hiring readiness

• Core questions
• Doctor costs rising—where is hiring still pending?
• Will doctor cost normalize and support margin expansion?
• Any start-up losses at Kalinga?
• Management response
• Hiring has been done across multi-location expansions; doctor additions are “quite secular” with some lumpiness.
• Belief: doctor cost should start giving operating leverage; marginal percentages come down.
• Kalinga is “already profitable” with “about INR 10-odd crore of EBITDA” (annual).
• Strength
• Provides a direct answer on Kalinga profitability and frames doctor costs as manageable.

Theme F: Noida ramp-up status

• Core questions
• Update on Noida occupancy and whether it can reach network levels.
• Management response
• Noida ramped well: occupancy ~64–65%, “further room to grow.”
• Confident on trajectory: “Absolutely… go to Network level occupancy of say 75%,” with suggestion they may need additional beds.

Theme G: Regulatory/approval risks for pipeline

• Core questions
• Any delays due to approvals/clearances for FY28+ projects?
• Management response
• “No regulatory clearance is pending” beyond anticipated.
• Past delays attributed to GRAP-3, manpower shortage (LPG crisis), and forest/tree transplantation issues—framed as incident-based rather than systemic.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Brownfield commissioning
• “All the beds will be ready… over the next 2 to 3 months.”
• Gurgaon commissioning
• “expecting commissioning by the end of the year” (FY27).
• Gurgaon breakeven
• “breaking even within the year” (FY28).
• Capacity additions
• Expect “another 10% capacity” once 500-bed Gurgaon commissioned during the year.
• Lucknow greenfield capex
• Board approved INR 1,400 crore for 700-bed Shaheed Path hospital.
• Project commissioning targets (selected)
• Sector-56 Gurgaon: commission by end of this year (FY27).
• Max Nagpur 100 beds: commissioning by FY28.
• Zirakpur/Mohali 400 beds: commission in FY28.
• Max Dwarka 260 beds: expected 24 months after approvals.
• Max Patparganj 400 beds: commissioning by FY29.
• Max Vaishali 200 beds: 24 months post approvals.

Implicit signals (qualitative)

• Margins: management repeatedly states “no real pressure on margins” at consolidated level despite oncology disruption.
• Oncology mix: oncology share likely to stay lower (21–22%) rather than revert.
• Operating leverage: expects leverage as beds ramp and costs become non-linear.
• Risk posture: approvals delays are attributed to past external incidents; current pipeline framed as on track.

5. Standout Statements (direct / high-signal)

• Capacity ramp confidence
• “All the beds will be ready to be operationalized over the next 2 to 3 months.”
• EBITDA contribution timing
• “So they are already contributing to EBITDA…”
• Oncology structural change
• “some of this is permanent… we do not expect the share of oncology come back to 25–26%… hover around 21–22%.”
• CGHS benefit remaining
• “INR 30-40 crore is yet to flow… about INR 100-110 crore has already flown.”
• Gurgaon breakeven
• “breaking even within the year” (FY28).
• Kalinga profitability
• “It is already profitable… about INR 10-odd crore of EBITDA.”
• Margin stance
• “on a consolidated basis, what we have seen is that there is no real pressure on margins.”
• Noida occupancy aspiration
• “Absolutely… go to… 75%.”

6. Red Flags / Positive Signals

Positive signals
– Strong operational metrics: occupancy >75%, OBDs up 8% YoY, revenue up 10% YoY in Q4.
– Net debt improving: net debt down vs Dec’25; net debt/EBITDA “less than 1.”
– Clear explanation of oncology/CGHS mechanics with quantified impacts.
– Kalinga acquisition framed as immediately profitable (reduces integration risk).

Red flags
– Oncology reversal not expected: management explicitly says oncology share will not return to prior levels—this is a structural headwind to mix and potentially long-term growth/margins.
– Limited transparency on consolidated EBITDA drag from new towers: “very tough to do it now” due to patient/specialty mixing—reduces ability to validate ramp economics.
– CGHS benefit timing remains qualitative (“next few months / during the year”), with no strict quarter-by-quarter certainty.
– Some reliance on “should” language for ramp and occupancy at new sites.

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

• Current (May 22, 2026): Optimistic
• Prior calls (Feb 6, 2026; Nov 17, 2025; Aug 14, 2025): also broadly optimistic, but with more emphasis on “temporary” disruptions.
• Shift: current call is more confident on execution timelines (brownfields in 2–3 months; Gurgaon end-FY27) and more definitive that oncology impact is permanent.
• Classification: More Optimistic on execution, but more cautious/realistic on oncology normalization (less hope of reverting to old mix).

b. Tracking Past Commitments vs Outcomes

• Brownfield ramp “in line with expectations” (Q3 FY26 call, Feb 6, 2026)
• Past: Nanavati/Mohali brownfield beds commissioned with remaining beds expected in Q4.
• Current: management now states phased commissioning of >20% additional brownfield capacity and that beds will be operationalized in 2–3 months.
• Assessment: ✅ Generally delivered (no evidence of major slippage; current narrative continues ramp).
• Gurgaon commissioning timing
• Feb call: Sector-56 Gurgaon first phase expected by end of H1 FY27.
• Current: commissioning expected by end of FY27.
• Assessment: ⏳ Delayed / pushed out (H1 FY27 → end-FY27).
• CGHS benefit timing
• Nov call: expected favorable impact “over INR 200 crore once fully implemented,” with super-specialty rates expected around late Nov/early Dec (discussed as near-term).
• Current: says “All except the super specialty rates” started; remaining INR 25–30 crore per annum to phase out; also oncology discontinuation already fully impacted Q4.
• Assessment: ⏳ Partially delivered (benefit exists, but super-specialty portion still pending).
• Oncology normalization
• Earlier (Nov/Feb): oncology disruption discussed as tied to CGHS pricing and negotiations; tone implied potential resolution.
• Current: explicit permanence—“some of this is permanent… hover around 21–22%.”
• Assessment: ❌ Not delivered as previously implied (narrative moved from “discussion/clearing” to “structural cap on share”).

c. Narrative Shifts

• Oncology story changed materially
• Earlier: oncology share/mix discussed with expectation of future adjustment as CGHS negotiations resolve.
• Now: management states oncology share will not revert to prior levels and that discontinuation is margin-driven and permanent.
• Risk framing on approvals
• Earlier calls referenced GRAP-3, manpower shortages, forest/tree issues as causes of delays.
• Current: says “No regulatory clearance is pending” beyond anticipated, implying improved visibility/control.
• Growth driver emphasis
• Earlier: growth framed as capacity + payor mix + CGHS.
• Current: growth framed as capacity ramp + operating leverage, while CGHS/oncology are treated as mix/margin modifiers rather than primary growth engines.

d. Consistency & Credibility Signals

• Credibility: Medium
• Strength: management provides quantified impacts (oncology/CGHS) and operational metrics.
• Weakness: timing slippage on Gurgaon (H1 FY27 → end FY27) and limited ability to quantify EBITDA drag from new towers.
• Oncology narrative has shifted from “to be cleared” to “permanent,” which can be seen as a credibility hit unless clearly explained as policy economics.

e. Evolution of Key Themes

• Demand/occupancy: Stable-to-strong (occupancy consistently >75% in Q4; earlier base hospitals ~80%).
• Margins: Management claims consolidated stability; however, oncology mix change suggests ongoing margin/mix trade-offs.
• Expansion: Execution remains central; brownfields are treated as accretive and fast-ramping.
• Regulatory risk: framed as episodic external events; current pipeline “no pending clearances.”

f. Additional Insights (Cross-Period Intelligence)

• The oncology/CGHS issue appears to have evolved from negotiation-driven to economics-driven:
• Management now explicitly ties discontinuation to inability to supply at required discounts (“we will not be able to do this kind of a business on the minus-margin basis”).
• Gurgaon timing drift suggests either construction/operational sequencing challenges or conservative reforecasting; management now uses analogies (Dwarka) to maintain confidence rather than providing new hard loss metrics.
• Management’s repeated emphasis on non-linear cost behavior and “already contributing to EBITDA” suggests they are actively managing investor expectations around ramp economics.